Biotech Investors & VC Firms in Norway

26 firms in this list, with a median first check of $425.5K. 9 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
NE New Enterprise Associates (NEA) AJABASAJ71 people · Leads rounds	88🔒	Menlo Park	US	Seed–Late Stage	$200K – $40M	+ Add to CRM
IN Investinor EJJO49 people	88🔒	Trondheim	NO	Pre-Seed–Late Stage	—	+ Add to CRM
PR Procuritas JCMFDSJH32 people · Leads rounds	88🔒	Stockholm	SE	Growth	—	+ Add to CRM
UN Unruly Capital SBFMFN3 people	88🔒	London	GB	Pre-Seed–Series A	—	+ Add to CRM
HE HealthCap MSTRVMAF30 people	88🔒	Stockholm	SE	Seed–Growth	—	+ Add to CRM
FA Farvatn Venture JO1 person	88🔒	Bergen	NO	—	—	+ Add to CRM
PR PreSeed Ventures AVAKCPHU31 people	88🔒	Kongens Lyngby	DK	Pre-Seed–Seed	—	+ Add to CRM
VO Voima Ventures IMJEJSPS12 people · Leads rounds	88🔒	Helsinki	FI	Pre-Seed–Series B	$216K – $3.2M	+ Add to CRM
AC ACME Capital A(AFCTHN12 people · Follows rounds	88🔒	San Francisco	US	Pre-Seed–Growth	—	+ Add to CRM
SA Sarsia Management AS SHESFAHS13 people · Leads rounds	88🔒	Bergen	NO	Seed–Series A	$190K – $475K	+ Add to CRM
SA Sandwater KMMEMWAU12 people · Leads rounds	88🔒	Oslo	NO	Seed–Series B	$2.2M – $11M	+ Add to CRM
EI EIR Ventures AHMPSCLB10 people · Leads rounds	88🔒	Stockholm	SE	Seed–Growth	—	+ Add to CRM
NO Nordic Science Investments AGAUDAJS8 people · Leads rounds	88🔒	Helsinki	FI	Pre-Seed–Series B	$55K – $3.9M	+ Add to CRM
AE Aescap Life Sciences PKPDBJGH14 people	88🔒	Amsterdam	NL	Seed–Growth	—	+ Add to CRM
EU Eurazeo LGLMMTNW12 people	88🔒	Paris	FR	Series A–Late Stage	—	+ Add to CRM
CA CapMan HHDJIMJK4 people	88🔒	Helsinki	FI	Series A–Late Stage	$2.2M – $64.8M	+ Add to CRM
VE Vesalius Biocapital III Partners SàRL CSGGMLCW12 people	88🔒	Contern	LU	Seed–Late Stage	$10.8M	+ Add to CRM
TE TeleVenture Management AS RRDTJARS11 people	88🔒	Oslo	NO	Seed–Series A	—	+ Add to CRM
PR Propagator Ventures AFAEETAA7 people	88🔒	Oslo	NO	Pre-Seed–Series A	—	+ Add to CRM
NO Nordic Capital KMCHHJJS7 people · Leads rounds	88🔒	Frankfurt am Main	DE	Growth–Late Stage	—	+ Add to CRM
P5 P53 Invest SSLMKSØS5 people	88🔒	Stavanger	NO	Seed–Series A	—	+ Add to CRM
CU Curitas Ventures GMMACAMB4 people	88🔒	Stockholm	SE	Seed–Series B	—	+ Add to CRM
AL Alpina Partners FSPS2 people · Leads rounds	88🔒	Munich	DE	Series A–Late Stage	$635K – $2.5M	+ Add to CRM
UN Unconventional Ventures NBTMVB3 people · Follows rounds	88🔒	Copenhagen	DK	Pre-Seed–Series A	—	+ Add to CRM

New Enterprise Associates (NEA)

Menlo ParkSeed–Late Stage$200K – $40M

AJABASAJ71 people

Investinor

TrondheimPre-Seed–Late Stage

EJJO49 people

Procuritas

StockholmGrowth

JCMFDSJH32 people

Unruly Capital

LondonPre-Seed–Series A

SBFMFN3 people

HealthCap

StockholmSeed–Growth

MSTRVMAF30 people

Farvatn Venture

Bergen

JO1 person

PreSeed Ventures

Kongens LyngbyPre-Seed–Seed

AVAKCPHU31 people

Voima Ventures

HelsinkiPre-Seed–Series B$216K – $3.2M

IMJEJSPS12 people

ACME Capital

San FranciscoPre-Seed–Growth

A(AFCTHN12 people

Sarsia Management AS

BergenSeed–Series A$190K – $475K

SHESFAHS13 people

Sandwater

OsloSeed–Series B$2.2M – $11M

KMMEMWAU12 people

EIR Ventures

StockholmSeed–Growth

AHMPSCLB10 people

Nordic Science Investments

HelsinkiPre-Seed–Series B$55K – $3.9M

AGAUDAJS8 people

Aescap Life Sciences

AmsterdamSeed–Growth

PKPDBJGH14 people

Eurazeo

ParisSeries A–Late Stage

LGLMMTNW12 people

CapMan

HelsinkiSeries A–Late Stage$2.2M – $64.8M

HHDJIMJK4 people

Vesalius Biocapital III Partners SàRL

ConternSeed–Late Stage$10.8M

CSGGMLCW12 people

TeleVenture Management AS

OsloSeed–Series A

RRDTJARS11 people

Propagator Ventures

OsloPre-Seed–Series A

AFAEETAA7 people

Nordic Capital

Frankfurt am MainGrowth–Late Stage

KMCHHJJS7 people

P53 Invest

StavangerSeed–Series A

SSLMKSØS5 people

Curitas Ventures

StockholmSeed–Series B

GMMACAMB4 people

Alpina Partners

MunichSeries A–Late Stage$635K – $2.5M

FSPS2 people

Unconventional Ventures

CopenhagenPre-Seed–Series A

NBTMVB3 people

Data sourced from public filings and firms' own websites — see our methodology.